TriangleHEALTH PROFESSIONAL · SOURCE READING
Adjuvant chemotherapy
Source: Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 15, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Congenital Mesoblastic Nephroma / Treatment of Congenital Mesoblastic Nephroma
Adjuvant chemotherapy has been recommended for patients with stage III cellular subtype mesoblastic nephromas who are aged 3 months or older at diagnosis.[5] In a study of stage III cellular type congenital mesoblastic nephroma, 7 of 12 patients who were treated with surgery only suffered from a relapse, while 4 of 14 patients who were treated with adjuvant chemotherapy (primarily dactinomycin/vincristine and sometimes doxorubicin) developed a relapse.[1,5,13] Cyclophosphamide and ifosfamide have been combined with these agents and have shown activity.[14]
Infants younger than 2 months with incompletely resected, stage III disease may not need chemotherapy.[1]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice